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contacts with clandestine gold pan-
ners, mainly Brazilian illegal resi-
dents. This population, in which
malaria incidence is almost impossi-
ble to evaluate, comes from Amapa
State, where the incidence of malaria
is increasing (5). In 2003, 60.9% of
patients with malaria cases at
Cayenne Hospital had a Brazilian
name compared with 35.4% in 2000
(6). Also, the gold panners diverted
the river and built basins where vec-
tors could easily multiply (7).
Initial malaria attacks were treated
with chloroquine or quinine. Five
patients experienced >1 relapses
(maximum 3 relapses). The relapses
were treated with 50-mg daily doses
of primaquine for 4 patients and by
chloroquine for the fifth patient. Two
patients had relapses after receiving
primaquine. Primaquine resistance
information was not available.
However, resistance to primaquine
has emerged in P. vivax strains (8).
We recommended that pre-impreg-
nated battlefield uniforms be available
for French policemen and chemopro-
phylaxis adherence be reinforced by
directly observed intake by superviso-
ry staff. Relapses of P. vivax malaria
are a major therapeutic problem, par-
ticularly after primaquine therapy.
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Plasmodium vivax
Malaria Relapses
after Primaquine
Prophylaxis 
To the Editor: Standard treatment
of patients with Plasmodium vivax
malaria includes chloroquine, fol-
lowed by primaquine terminal pro-
phylaxis. Reports of true primaquine
failure and subsequent P. vivax
relapse are unusual; most suspected
cases can be ascribed to poor patient
adherence, recrudescence of a chloro-
quine-resistant strain, or P. vivax rein-
fection. We report a case of P. vivax
malaria relapse after therapy with qui-
nine, doxycycline, and primaquine,
and again after treatment with chloro-
quine and primaquine. P.  vivax
relapses after primaquine treatment
are exceedingly rare in travelers to
South America and are a serious ther-
apeutic challenge. Our patient was
subsequently treated with weekly, sin-
gle-dose chloroquine without recur-
rence of symptoms.
A 77-year-old man had fever and
chills 2 weeks after returning from
Brazil. These symptoms were accom-
panied by sweating, fatigue, and a
mild, productive cough. Review of
systems was notable for dark, con-
centrated urine and a 10-lb weight
loss. The patient’s 25-day journey
included Salvador, Manaus, and a 2-
day stay in the Amazon River basin.
He did not take malaria prophylaxis
during his trip.
On physical examination, the
patient was afebrile with blood pres-
sure of 90/53 mm Hg. Cardio-
vascular, pulmonary, and abdominal
examination results were unremark-
able. Several petechiae were noted on
both lower extremities. Laboratory
tests showed the following: leukocyte
count 6,300 cells/µL, hemoglobin
level 13.7 g/dL, platelet count 40,000
cells/µL, serum creatinine level 1.2
mg/dL, serum alanine aminotrans-
ferase level 63 IU/L, and serum
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aspartate  aminotransferase level 56
IU/L. Thick and thin peripheral blood
smears revealed P. vivax with a para-
sitemia level of 0.67%. Although the
existence of chloroquine-resistant P.
vivax in Brazil is debatable, the
patient was conservatively treated
with quinine, 650 mg, 3×/day and
doxycycline, 100 mg, 2×/day for 7
days, followed by primaquine termi-
nal prophylaxis, 30 mg/day for 30
days with complete resolution of
symptoms.
In the absence of travel abroad, the
patient experienced similar symptoms
5 months later. On the basis of thick
and thin peripheral blood smear
examination, a relapse of P.  vivax
malaria was diagnosed. He was given
chloroquine, 2.5 g over 3 days, fol-
lowed by primaquine, 30 mg/day for
30 days. Again, the patient’s symp-
toms resolved.
Four months after treatment (9
months after the initial episode), the
patient experienced the abrupt onset
of fever, chills, and dark urine. He had
a leukocyte count of 5,900 cells/µL, a
hemoglobin level of 14.0 g/dL, and a
platelet count of 117,000 cells/µL.
Repeat thick and thin blood smears
showed  P.  vivax  with a parasitemia
level of 0.993%. Therapy with chloro-
quine was initiated (2.5 g over 3
days), and symptoms resolved.
Repeat blood smears 4 days later were
negative for P. vivax. In lieu of yet
another course of terminal prophylax-
is with primaquine, the patient was
given chloroquine, 300 mg/week for 4
months; he has been asymptomatic
for an additional 2 months.
Even before Food and Drug
Administration approval of pri-
maquine in 1951, primaquine failure
was documented in experimental
cases of the Chesson (tropical) P.
vivax strain (1). Additional reports
soon followed, citing dosing differ-
ences as the likely reason for P. vivax
relapse. Baird and Hoffman summa-
rized cases of primaquine failure over
nearly 3 decades, noting that 26
(25%) of 103 patients given pri-
maquine, 15 mg/day for 14 days,
relapsed, while infection returned in
only 1 (3.9%) of 26 patients given
22.5–30 mg/day (2). Among 50
patients treated for P. vivax malaria in
Brazil, total primaquine dose per
patient was the only variable in
relapse; 7 relapses occurred in
patients who received 2.76 mg/kg,
while those who received 3.35 mg/kg
remained free of infection (3). As a
consequence, patients weighing >70–
80 kg should receive 0.5 mg/kg/day
(2).
The issue of primaquine resistance
in  P.  vivax remains unresolved for
several reasons. First, the organism
cannot be propagated in vitro, and
injection of P. vivax into nonhuman
primates is required for analysis (4).
Second, the pharmacokinetics of pri-
maquine are poorly understood.
Despite standard dose administration,
1 study suggested substantial intereth-
nic differences in peak plasma con-
centrations of primaquine and its
major metabolite, carboxyprimaquine
(5). Finally, confounding factors such
as drug dosing and patient compliance
have complicated most failure reports.
Our patient initially received qui-
nine and doxycycline, which excluded
a chloroquine-resistant infection. In
addition, he completed a primaquine
regimen of 10.8 mg/kg, which is twice
the current recommended dose. In the
absence of reexposure, the patient had
a relapse 5 months later. His condition
was treated with chloroquine and
again with high-dose primaquine. He
reported strict adherence to the treat-
ment regimen, citing the fastidious
use of a weekly pill box as evidence.
Despite these measures, another
relapse occurred 4 months later. This
patient’s course suggests P. vivax pri-
maquine failure and possible resist-
ance. When high-dose regimens of
primaquine (total 5–6 mg/kg) fail,
suppressive doses of chloroquine, 300
mg/week for several months to years
may be considered. Our patient
received chloroquine therapy, 300
mg/week for the past 4 months with-
out evidence of recurrence. 
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